ANNEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED 
BY THE MEMBER STATES 
The  Marketing  Authorisation  Holder  shall  ensure  that  all  physicians  who  are  expected  to 
prescribe Vectibix are provided with educational materials informing them of the importance of 
KRAS  ascertainment  before  treatment  with  panitumumab.  The  key  elements  of  these 
educational materials will be the following: 
• 
• 
• 
Brief introduction to the Vectibix indication and the purpose of this tool 
Brief introduction to KRAS and its role in the panitumumab mechanism of action  
Information that in patients with mutant KRAS tumours panitumumab has shown a detrimental 
effect in combination with FOLFOX and no effect as monotherapy and in combination with 
FOLFIRI  
Recommendation that Vectibix: 
o  
o  
should only be used in patients whose tumours are wild-type KRAS 
should not be used as monotherapy or in combination with FOLFIRI in patients whose 
tumours are mutant KRAS or patients whose tumours have not been tested for KRAS 
status 
is contraindicated in combination with FOLFOX in patients with mutant KRAS tumours 
or in patients with unknown KRAS tumour status 
o  
• 
• 
Information on how the KRAS testing should be appropriately conducted 
The Marketing Authorisation Holder shall agree the format and content of the above materials with the 
National Competent Authority of each Member State. 
 
 
